stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) EV/FCF
As of 6 November 2026, PTC Therapeutics, Inc. (PTCT) trades at a EV/FCF of −23.9×. Over the past ten years it has ranged from −4,980× (June 2018) to 502× (October 2018); the current reading is higher than 13% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 15.1× | — |
| FY2024 | −20.4× | — |
| FY2023 | −10.3× | — |
| FY2022 | −7.2× | — |
| FY2021 | −8.9× | — |
| FY2020 | −14.4× | — |
| FY2019 | −16.5× | — |
| FY2018 | −43.9× | — |
| FY2017 | −48.5× | — |
| FY2016 | −2.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −23.6× | — |
| Jun 2026 | −24.8× | — |
| Mar 2026 | −13.1× | — |
| Dec 2025 | 15.1× | 22.28% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −79.2× |
| MANE Veradermics Incorporated compare | −35.5× |
| KOD Kodiak Sciences Inc. compare | −35.4× |
| CGON CG Oncology, Inc. compare | −26.2× |
| PTCT PTC Therapeutics, Inc. | −24.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −21.1× |
| SRRK Scholar Rock Holding Corporation compare | −19.0× |
| COGT Cogent Biosciences, Inc. compare | −14.6× |
| IMVT Immunovant, Inc. compare | −12.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement